This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

(Hypertension. 2005;46:923.)
© 2005 American Heart Association, Inc.

Awards

2005 IASH Lifetime Achievement Award

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Artur B. Ribeiro, MD, is a Brazilian nephrologist whose research has advanced understanding and treatment of high blood pressure. A graduate of the Federal University of São Paulo, Escola Paulista de Medicina, in 1969, Dr Ribeiro pursued postgraduate training in nephrology and hypertension at Cornell University Medical Center, Nephrology Division, and Mount Sinai School of Medicine, Hypertension Division in New York, between 1973 and 1976. At his postgraduate training, Dr Ribeiro joined Dr Haralambos Gavras and Dr Lawrence Krakoff, pioneers in hypertension research, and, under their mentorship, initiated a program of research on the role of the renin-angiotensin system in experimental and clinical hypertension.

On his return to Brazil in 1976, Dr Ribeiro became professor at the Federal University of São Paulo, Escola Paulista de Medicina, Nephrology Division, where he is the Chief of the Hypertension Section and served as Past President of the Oswaldo Ramos Foundation, Kidney and Hypertension Hospital. He developed an extensive research program in experimental and clinical hypertension and mentored many physicians who have become medical leaders and university professors in different regions of Brazil.

Dr Ribeiro’s research encompasses multiple areas of hypertension on both experimental and clinical aspects, including the role of the renin-angiotensin and kallikrein-kinin systems, the role vasopressin V-1 receptor, and renal damage in hypertension and diabetes, as well as his recent studies on the glucose metabolism disturbances in hypertension. He has also participated as an investigator in many Clinical Trials in Hypertension, and was a member of the steering committee of the . . . [Full Text of this Article]